New Delhi, Feb 25 (IANS) New research into GLP-1 receptor has opened a realm of new treatment possibilities to treat opioid use disorder (OUD), a report said on Tuesday.
A three-week Phase I study conducted at the Caron Treatment Centers in Pennsylvania in the US, enrolling 20 participants undergoing residential treatment for OUD, assessed Novo Nordisk’s Saxenda (liraglutide), a GLP-1 receptor agonist (GLP-1RA), as a monotherapy for OUD.
The study displayed its potential to rival existing treatments and showed a 40 per cent reduction in opioid cravings among those taking Saxenda, according to GlobalData, a leading data and analytics company.
Originally developed for treating diabetes, GLP-1RAs work by stimulating insulin secretion and suppressing glucagon release, thereby helping regulate blood sugar.
“However, there are GLP-1 receptors in the brain’s mesolimbic system, which is inextricably linked to motivation and reward. This has piqued the interest of drug developers looking to expand the label of their products to combat the opioid crisis,” said Jos Opdenakker, pharma analyst at GlobalData.
Early clinical work has shown that GLP-1RAs are a promising new avenue in the treatment of OUD, as the current treatment landscape is stifled by a lack of innovation and a heavy reliance upon opioid agonist therapies, he noted.
According to GlobalData’s Drug Database, six out of the seven agents currently in late-stage development (Phase IIb–III) are non-opioids.
Currently, there is a lack of available efficacy data for many of the pipeline agents. Therefore, despite the presence of non-opioids in the pipeline, high-efficacy non-opioid OUD treatments remain an exploitable opportunity.
In addition to OUD, GLP-1RAs are also being investigated in other neurology indications, such as to treat Alzheimer’s disease and associated cognitive impairment, Parkinson’s disease, alcohol dependence, peripheral neuropathy, and intracranial hypertension.
Developers have recognised the potential of GLP-1RAs, and a new class of neurological agents is developing.
—IANS
na/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
